End of obe­si­ty drug short­age threat­ens pa­tient ac­cess to com­pound­ed shots that Lil­ly calls risky

Tele­health com­pa­nies and pa­tients are grap­pling with the po­ten­tial loss of ac­cess to cheap­er, al­ter­na­tive ver­sions of Eli Lil­ly’s pop­u­lar GLP-1 weight loss drug tirzepatide …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER